"Living my best life is striking the balance between work and family. I am fortunate to see the impact of the work we do at Avivagen and work very hard, while enjoying time with my family."
Kym is the CEO of Avivagen. He has extensive experience in capital markets, agriculture and life sciences. Kym is the current chair of Hybrid Partners and is the Executive Chair of Top Meadow Investments, Inc. He is also the previous chair of Prometic Life Sciences Inc.
"I enjoy the moments of understanding that science brings to our projects, contributing to the successful development of health products."
Graham, a co-founder of Avivagen, comes with a background as a leading scientist in vitamin E research at the National Research Council of Canada (NRC). His later research activities became the foundation for Avivagen’s oxidized β-carotene technology.
"Helping entrepreneurial companies like Avivagen navigate through growth phases. And playing with my dog!"
David brings years of experience to Avivagen as the former President and CEO of Solvay Pharma Inc. He also co-founded a pharmaceutical distribution operation as VP of Kingswood Canada Inc. and has 15 years of experience in various positions at Eli Lilly.
"My passion is helping both public and private companies as they strive to grow and differentiate their story from the crowd."
Chief Executive Officer and Co-Founder, Crystal Research Associates LLC
Mr. Kraws ranks in the top ten analysts for pharmaceutical stock performance in the world, and Starmine and Zacks have both ranked him as number one stock picker for pharmaceuticals. His experience includes Senior Pharmeceutical Analyst at Evern Securities, Asea Brown Boveri, Nationsbanc Montgomery Securities, BT Alex Brown & Sons and The Buckingham Research Group Incorporated.
He holds an MBA from Cornell University and a B.S. degree from State University of New York-Buffalo.
"As you get older, you realize the importance of being able to do the things you want to do. Sometimes health and mobility issues can slow you down, so doing what we can to maintain our health is important in living our best life."
Mr. Aubrey Dan is a Canadian businessman, philanthropist and Tony-Award® winning producer (MEMPHIS) as well as the Principal of the Dancap Family Investment Office (dancap.ca).
Mr. Dan joined Novopharm Ltd. following his graduation from Western University in the role of Sales Representative, progressing to the position of Director of Sales. He later served as President of Wampole Canada Inc., a Novopharm subsidiary, until the acquisition of Novopharm by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA | TASE:TEVA) in 2000.
"By helping companies at the forefront of medical research to bring innovative new solutions to the marketplace."
Mr. Paul Mesburis is the Managing Principal of Empyrean Capital, and has more than twenty years of international experience in financial and capital markets. On the buy-side, he has managed portfolios for global investment strategies in both debt and equities. On the sell-side, his experience includes senior roles in mergers and acquisitions, investment banking, and institutional equity research at HSBC Securities, Scotiabank Global Banking and Markets and Deutsche Bank Securities. In 2012, he was honoured with a Canadian Lipper Fund Award which recognizes funds that have excelled in delivering consistently strong risk-adjusted performance, relative to their peers.